Differentiation of cerebral metastases of lung cancer using apparent diffusion coefficient (ADC) maps

Differentiation of cerebral metastases of lung cancer using apparent diffusion coefficient (ADC) maps - LUMETADC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023016

Enrollment

600

Registered

2020-09-07

Start date

2020-07-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34 C79.3

Interventions

Group 1: Patients with histologically comfirmed SCLC or NSLC and an MRI in our data archieving system between 01.01.2009 to 01.01.2020.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with pathologically confirmed SCLC or NSCLC and an MRI of the brain, regardless of the MRI manufacturer or the field strength. It must only contain (i) a T1-weighted sequence with contrast agent (CA), (ii) a T2-weighted sequence for detecting zystic parts and (iii) a DWI Sequence with ADC Mapping.

Exclusion criteria

Exclusion criteria: Patients are excluded, if (1) brain metastasis are not detected by MRI, (2) the size of the found solid tumour parts were not large enough (50% of the solid tumour part) were excluded.

Design outcomes

Primary

Measure	Time frame
We want to analyzed, if (i) a reliable differentiation between SCLC and NSCLC using ADC maps is possible	—

Secondary

Measure	Time frame
and, (ii) if ADC values under systemic therapy can be used as therapy control.	—

Countries

Germany

Contacts

Public ContactSebastian Mueller

Universitätsmedizin Göttingen

sebastian.mueller@med.uni-goettingen.de017621243799

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 23, 2026